SARS-CoV‑2 Mpro Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals

The main protease of SARS-CoV-2 (Mpro) is the most promising drug target against coronaviruses due to its essential role in virus replication. With newly emerging variants there is a concern that mutations in Mpro may alter the structural and functional properties of protease and subsequently the po...

Full description

Saved in:
Bibliographic Details
Published in:ACS central science 2023-04, Vol.9 (4), p.696-708
Main Authors: Chen, Sizhu Amelia, Arutyunova, Elena, Lu, Jimmy, Khan, Muhammad Bashir, Rut, Wioletta, Zmudzinski, Mikolaj, Shahbaz, Shima, Iyyathurai, Jegan, Moussa, Eman W., Turner, Zoe, Bai, Bing, Lamer, Tess, Nieman, James A., Vederas, John C., Julien, Olivier, Drag, Marcin, Elahi, Shokrollah, Young, Howard S., Lemieux, M. Joanne
Format: Article
Language:English
Subjects:
crystal cleavage
genetics
INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
monomers
peptides and proteins
SARS-CoV-2
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main protease of SARS-CoV-2 (Mpro) is the most promising drug target against coronaviruses due to its essential role in virus replication. With newly emerging variants there is a concern that mutations in Mpro may alter the structural and functional properties of protease and subsequently the potency of existing and potential antivirals. We explored the effect of 31 mutations belonging to 5 variants of concern (VOCs) on catalytic parameters and substrate specificity, which revealed changes in substrate binding and the rate of cleavage of a viral peptide. Crystal structures of 11 Mpro mutants provided structural insight into their altered functionality. Additionally, we show Mpro mutations influence proteolysis of an immunomodulatory host protein Galectin-8 (Gal-8) and a subsequent significant decrease in cytokine secretion, providing evidence for alterations in the escape of host-antiviral mechanisms. Accordingly, mutations associated with the Gamma VOC and highly virulent Delta VOC resulted in a significant increase in Gal-8 cleavage. Importantly, IC50s of nirmatrelvir (Pfizer) and our irreversible inhibitor AVI-8053 demonstrated no changes in potency for both drugs for all mutants, suggesting Mpro will remain a high-priority antiviral drug candidate as SARS-CoV-2 evolves.
ISSN:2374-7943
2374-7951
DOI:10.1021/acscentsci.3c00054